HER2 Support Group Forums - View Single Post - Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pai

News · 04-02-2012, 07:20 AM

Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.

More...

04-02-2012, 07:20 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 19,006	Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pai Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate. More...